Home Newsfeeds Baird Maintains Outperform on Rapid7, Lowers Price Target to $56

Baird Maintains Outperform on Rapid7, Lowers Price Target to $56

Baird analyst Shrenik Kothari maintains Rapid7 (NASDAQ:RPD) with a Outperform and lowers the price target from $58 to $56.

byBenzinga Newsdesk

February 9, 2023

1 minute read

Baird analyst Shrenik Kothari maintains Rapid7 (NASDAQ:RPD) with a Outperform and lowers the price target from $58 to $56.

Reported Late Friday March 17, Arbor Realty Trust Announces $50M Share Repurchase Program

By Happy Mohamed

March 18, 1:38 AM

Arbor Realty Trust, Inc. (NYSE:ABR), today announced that its Board of Directors has approved a share repurchase program authorizing the Company to repurchase up to $50 million of its outstanding common stock.

ABR

CORRECTION: Phathom Pharmaceuticals Announces Proposed Public Offering Of Common Stock; Intends To Grant The Underwriters A 30-Day Option To Purchase Up To An Additional 15% Of The Total Number Of The Shares Of Its Common Stock Offered

By Happy Mohamed

May 23, 4:08 PM

Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell,

PHAT

Penny Stock Moleculin Highlights Interim Data From Blood Cancer Study With Complete Response Rate of 38%

By Vandana Singh

November 13, 1:18 PM

Moleculin Biotech Inc (NASDAQ: MBRX) provided a preliminary update on recent clinical activity from annamycin

MBRX

These 3 Energy Stocks With Over 3% Dividend Yields Are Recommended By Wall Street’s Most Accurate Analysts

By Lisa Levin

March 8, 9:35 AM

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.

CVX

Baird Maintains Outperform on Rapid7, Lowers Price Target to $56

Related Posts

Reported Late Friday March 17, Arbor Realty Trust Announces $50M Share Repurchase Program

CORRECTION: Phathom Pharmaceuticals Announces Proposed Public Offering Of Common Stock; Intends To Grant The Underwriters A 30-Day Option To Purchase Up To An Additional 15% Of The Total Number Of The Shares Of Its Common Stock Offered

Penny Stock Moleculin Highlights Interim Data From Blood Cancer Study With Complete Response Rate of 38%

These 3 Energy Stocks With Over 3% Dividend Yields Are Recommended By Wall Street’s Most Accurate Analysts